

One gel
EstroGel® 0.06% (estradiol gel) is the first and only non-patch, non-film transdermal estrogen indicated for treatment of both1
![]() |
Moderate to severe symptoms of vulvar and vaginal atrophy (VVA) due to menopause* |
* | When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.1 |
![]() |
Moderate to severe vasomotor symptoms (VMS) due to menopause |
Estrogen-alone therapy may increase the risks of stroke, deep vein thrombosis, endometrial cancer and dementia, and estrogen plus progestin therapy may increase the risks of invasive breast cancer, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction and dementia.1
One arm
No need for application site rotation.1
EstroGel is applied to the entire arm on the inside and outside from wrist to shoulder.1
One pump
One press of the pump delivers 1.25 g of gel containing 0.75 mg estradiol.1
One hour
No measurable transfer of estradiol 1 hour after application in clinical study of nondosed healthy postmenopausal females (n=24) after direct skin-to-skin contact with subjects administered EstroGel.1
One level
Appeared to reach steady serum concentrations after 3 days†; approximately 36-hour half-life.1
† | Steady state achieved after the third daily application of a 2.5-g dose of EstroGel (1.25 g on each arm); dose not approved in the United States (EstroGel Prescribing Information, Section 12.3).1 |
Treatment With ONE Gel
With one gel, treat both1
• | Moderate to severe vasomotor symptoms (VMS) due to menopause |
• | Moderate to severe symptoms of vulvar and vaginal atrophy (VVA) due to menopause |
When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered1 |
Moderate to severe symptoms of VVA due to menopause may include2
• | Vaginal dryness |
• | Vaginal and/or vulvar irritation/itching |
• | Vaginal pain associated with sexual activity |
Order samples or patient education materials: contact your local EstroGel representative or call ASCEND Therapeutics at 1-855-786-0738. |
References: 1. EstroGel [package insert]. Herndon, VA: ASCEND Therapeutics; 2020. 2. Food and Drug Administration. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation. Draft guidance. Washington, DC; US Department of Health and Human Services; January 2003.